India's Translational Research Gap: Dr. Reddy's Whitepaper Maps Path from 'Pharmacy of the World' to Global Discovery Hub
Key Insights
India supplies ~20% of global generic drugs by volume but has produced few globally marketed novel drugs, highlighting a persistent gap between laboratory discovery and commercial therapies.
A new Dr. Reddy's whitepaper identifies fragmented pathways, funding shortages, and weak academia-industry linkages as key bottlenecks stalling India's biomedical innovation ecosystem.
The report calls for dedicated translational funding mechanisms, strengthened regulatory capabilities, and integration of India's vast hospital networks and patient data into R&D pathways.
India, long celebrated as the "pharmacy of the world" for its dominance in generic drug manufacturing, stands at a critical crossroads in its ambition to become a global hub for drug discovery and biomedical innovation. A new whitepaper released by Dr. Reddy's Laboratories, titled "Translational Research Ecosystem: Learnings from the World & Building for India," argues that persistent gaps in funding, regulatory support, and collaboration between academia and industry are constraining the country's ability to convert laboratory discoveries into commercially viable therapies.
The report arrives at a pivotal moment. India accounts for approximately 20% of the world's generic drug supply by volume, yet has produced relatively few globally marketed novel drugs. The country's biotechnology industry is projected to grow from about $165 billion in 2024 to $300 billion by 2030, according to government estimates, intensifying the need for stronger mechanisms to translate scientific research into commercial products and therapies.
Fragmented Pathways and Persistent Bottlenecks
The whitepaper identifies what it describes as a fragmented pathway between early-stage scientific discovery and clinical development, resulting in promising innovations failing to reach patients. Key bottlenecks include funding shortages, lengthy regulatory processes, and limited engagement between researchers, industry, healthcare institutions, and investors.
"India stands at a critical inflection point in its innovation journey. To realise our ambition of becoming a global discovery hub, we need a step change, from incremental progress to innovation at scale," said Satish Reddy, Chairman of Dr. Reddy's Laboratories. "This requires stronger translational research pathways to ensure that scientific discoveries translate into meaningful patient impact."
Translational research — the process of moving scientific discoveries from laboratories into clinical applications, medicines, and healthcare solutions — remains underdeveloped in India despite the country possessing many foundational elements for a stronger innovation ecosystem. The report contends that India lacks the mechanisms required to connect research, development, regulation, and commercialisation effectively.
Underutilised Assets: Hospitals, Patient Data, and Clinical Research
One of the report's central arguments is that India's large hospital networks, patient pools, and real-world clinical data represent significantly underutilised assets that could accelerate medical innovation if integrated more effectively into research and development pathways. Industry experts have frequently noted that India accounts for a relatively small share of global clinical research activity despite having one of the world's largest patient populations, underscoring the need for stronger translational research infrastructure.
The findings are based on discussions held during the third annual roundtable convened by Dr. Reddy's ahead of the Dr. Anji Reddy Memorial Lecture Series. Participants included former WHO Chief Scientist Dr. Soumya Swaminathan, ANRF Chief Executive Officer Shivkumar Kalyanaraman, BITS Pilani Vice-Chancellor V. Ramgopal Rao, and other experts from academia, healthcare, and industry.
Policy Context and the ANRF
The report's release aligns with government efforts to strengthen research commercialisation and industry-academia collaboration through the Anusandhan National Research Foundation (ANRF), established in 2023. The ANRF aims to catalyse greater public and private investment in research and innovation, addressing the fragmentation that has historically characterised India's research system.
India's overall research and development spending remains modest at around 0.7% of gross domestic product, far below that of the United States, Europe, and China. However, public investment is rising, with a ₹1 lakh crore (US $12 billion) Research, Development and Innovation fund, plus an additional $1.2 billion for biopharma allocated this year.
Recommendations for Systemic Change
Among its key recommendations, the whitepaper calls for greater collaboration between universities, pharmaceutical companies, hospitals, funding agencies, and government bodies. It advocates expanding dedicated funding mechanisms to support innovations through the lengthy development cycle and strengthening regulatory capabilities through structured programmes or centres of excellence focused on innovation.
The report further argues that the success of the ecosystem should ultimately be measured by the number of innovations that reach patients and improve health outcomes, rather than by research output alone — a metric that would represent a fundamental shift in how India evaluates its biomedical research enterprise.
A "Third Way" for Indian Innovation
The challenges outlined in the Dr. Reddy's whitepaper resonate with broader analyses of India's innovation landscape. India is unlikely to follow the state-led model of China or the high-cost, market-driven system of the United States. Instead, the country is charting what some observers describe as a "third way" — combining frugal innovation with population diversity and digital infrastructure.
This approach is visible in a series of locally driven advances, from NexCAR19, India's first homegrown and affordable chimeric antigen receptor (CAR) T cell therapy, to the portable Truenat (search) platform for tuberculosis (search) diagnostics and the low-cost rotavirus vaccine Rotavac. Each of these examples is centered on affordability and local adaptability — principles that the whitepaper suggests must be scaled through stronger translational infrastructure.
With a population of 1.4 billion and an estimated 4,600 endogamous groups, India possesses invaluable population diversity, including unique disease-causing mutations. The GenomeIndia initiative, which mapped 10,000 genomes across 83 populations, is already revealing patterns of genetic variation largely invisible in Western cohorts. Scaling such efforts, combined with digital health infrastructure like the Ayushman Bharat Digital Mission — which links approximately 840 million people to digital health IDs — could substantially expand the resolution of population-scale biomedical variation.
The path forward, as the whitepaper makes clear, requires aligning investments, institutions, and inclusivity. Whether India can successfully bridge its translational research gap will determine whether the country transforms from the pharmacy of the world into a true global discovery hub.